In Focus Stocks: Johnson Outdoors Inc., Ennis (NYSE:EBF), Navios Maritime Acquisition Corporation (NYSE:NNA), Advaxis (NASDAQ:ADXS), Encana Corporation (NYSE:ECA)

Johnson Outdoors Inc. (NASDAQ:JOUT) shares moved down -3.67% in last trading session and ended the day at $19.69. JOUT Gross Margin is 39.90% and its has a return on assets of 3.30%. Johnson Outdoors Inc. (NASDAQ:JOUT) quarterly performance is -12.41%.

Johnson Outdoors Inc. (NASDAQ:JOUT), a global leader in innovative outdoor recreation equipment products, announced approval by its Board of Directors of a quarterly cash dividend of $0.080 per Class A share and $0.073 per Class B share. The quarterly cash dividend is payable on January 28, 2016 to shareholders of record at the close of business on January 14, 2016.

Ennis Inc. (NYSE:EBF) ended the last trading day at $19.20. Company weekly volatility is calculated as 4.30% and price to cash ratio as 36.17. Ennis Inc. (NYSE:EBF) showed a weekly performance of 1.59%.

Ennis Inc. (NYSE:EBF) announced that the Board of Directors on December 18, 2015 approved the payment of a quarterly cash dividend of 17 ½ cents a share on its common stock. The dividend is payable February 5, 2016 to shareholders of record on January 8, 2016.

On 19 January, Navios Maritime Acquisition Corporation (NYSE:NNA) shares moved up 2.42% and was closed at $2.12. NNA EPS growth in last 5 year was 34.10%. Navios Maritime Acquisition Corporation (NYSE:NNA) year to date (YTD) performance is -29.57%.

Advaxis, Inc. (NASDAQ:ADXS) shares moved down -4.95% in last trading session and ended the day at $6.91. ADXS has a return on assets of -61.10%. Advaxis, Inc. (NASDAQ:ADXS) quarterly performance is -35.30%.

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, announced that it has added two more patents to its growing patent portfolio. The first patent, European Patent No. 1804831, expands the composition of matter claims covering HER-2 tumor antigens. The second patent, U.S. Patent No. 9,226,958, expands the use of the Company’s Lm Technology™ beyond oncology, specifically to induce an immune response in parasitically infected patients.

Encana Corporation (NYSE:ECA) caters to the Basic Materials space. It has a net profit margin of -77.10% and weekly performance is -30.72%. On the last day of trading company shares ended up at $3.27. Encana Corporation (NYSE:ECA) distance from 50-day simple moving average (SMA50) is -48.69%.

Encana Co. (NYSE:ECA) had its price objective cut by stock analysts at Societe Generale from C$8.50 to C$7.50 in a report released on Monday, MarketBeat reports. The firm currently has a “hold” rating on the stock. Societe Generale’s target price would indicate a potential upside of 8.54% from the stock’s previous close.